362 related articles for article (PubMed ID: 37238666)
21. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
[TBL] [Abstract][Full Text] [Related]
22. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
[TBL] [Abstract][Full Text] [Related]
23. Role of chemotherapy in the treatment of gastroesophageal cancers.
Hwang JJ
Oncology (Williston Park); 2007 Apr; 21(5):579-86; discussion 587, 591-2. PubMed ID: 17536343
[TBL] [Abstract][Full Text] [Related]
24. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge.
Hicks DG; Whitney-Miller C
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):506-8. PubMed ID: 22089490
[TBL] [Abstract][Full Text] [Related]
25. Multidisciplinary Therapy of Esophageal Cancer.
Egyud MR; Tseng JF; Suzuki K
Surg Clin North Am; 2019 Jun; 99(3):419-437. PubMed ID: 31047033
[TBL] [Abstract][Full Text] [Related]
26. Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future.
Aggelis V; Cunningham D; Lordick F; Smyth EC
Ann Oncol; 2018 Jun; 29(6):1377-1385. PubMed ID: 29771279
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapies for esophageal cancer.
Tew WP; Kelsen DP; Ilson DH
Oncologist; 2005 Sep; 10(8):590-601. PubMed ID: 16177283
[TBL] [Abstract][Full Text] [Related]
28. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.
Jin Z; Holubek M; Sukov WR; Sattler CA; Wiktor AE; Jenkins RB; Wu TT; Yoon HH
Am J Clin Oncol; 2019 Feb; 42(2):190-195. PubMed ID: 30516569
[TBL] [Abstract][Full Text] [Related]
29. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y; Kawazoe A; Lordick F; Janjigian YY; Shitara K
Nat Rev Clin Oncol; 2021 Aug; 18(8):473-487. PubMed ID: 33790428
[TBL] [Abstract][Full Text] [Related]
30. Role of Immunotherapy in Advanced Gastroesophageal Cancer.
Terrero G; Lockhart AC
Curr Oncol Rep; 2020 Aug; 22(11):112. PubMed ID: 32803457
[TBL] [Abstract][Full Text] [Related]
31. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
32. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
[TBL] [Abstract][Full Text] [Related]
33. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
34. The management of localized esophageal squamous cell carcinoma: Western approach.
Zaidi N; Kelly RJ
Chin Clin Oncol; 2017 Oct; 6(5):46. PubMed ID: 29129086
[TBL] [Abstract][Full Text] [Related]
35. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
36. A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Cinar P; Calkins SM; Venook AP; Kelley RK
Anticancer Res; 2014 Dec; 34(12):7357-60. PubMed ID: 25503172
[TBL] [Abstract][Full Text] [Related]
37. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma.
Pericay C; Rivera F; Gomez-Martin C; Nuñez I; Cassinello A; Imedio ER
Cancer Med; 2016 Dec; 5(12):3464-3474. PubMed ID: 27774774
[TBL] [Abstract][Full Text] [Related]
38. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
Varadhachary G; Ajani JA
Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
[TBL] [Abstract][Full Text] [Related]
39. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer - Review article.
Klevebro F; Ekman S; Nilsson M
Surg Oncol; 2017 Sep; 26(3):290-295. PubMed ID: 28807249
[TBL] [Abstract][Full Text] [Related]
40. Clinical impact of tumour biology in the management of gastroesophageal cancer.
Lordick F; Janjigian YY
Nat Rev Clin Oncol; 2016 Jun; 13(6):348-60. PubMed ID: 26925958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]